V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330006143 | 330002918 | 1.53 | null | Palliative (P) | 2014-09-01 | 2014-09-01 | Melphalan IV High dose | 02 | N | 330006301 | CYTARABINE HIGH DOSE |
| 330006144 | 330011536 | 1.84 | 80.9 | Curative (C) | 2018-07-25 | 2018-08-06 | PEMBROLIZUMAB | N | N | 330009579 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330006145 | 330011536 | 1.77 | 108 | Palliative (P) | 2019-02-05 | 2019-02-18 | CETUXIMAB + CISPLATIN + FU | 02 | N | 330009579 | CVP |
| 330006146 | 330012736 | 1.58 | 9.7 | Palliative (P) | 2018-06-17 | 2018-06-17 | FLUOROURACIL + MITOMYCIN + RT | N | N | 330010688 | HYDROXYCARBAMIDE |
| 330006147 | 330002919 | 0 | 96.3 | Neo-adjuvant (N) | 2016-12-13 | 2016-12-13 | VAC | 02 | N | 330011257 | TEMOZOLOMIDE |
| 330006148 | 330002919 | null | 81.9 | Palliative (P) | 2014-09-25 | 2014-10-05 | POMB/ACE | null | null | 330011257 | CAV |
| 330006149 | 330002919 | 1.77 | 112 | Palliative (P) | 2013-01-02 | 2013-01-02 | EOX | Y | N | 330011257 | CYTARABINE HIGH DOSE |
| 330006150 | 330002919 | null | null | null | null | 2016-12-26 | BLEOMYCIN + CISPLATIN + VINCRISTINE | Y | N | 330011257 | GEMCITABINE |
| 330006151 | 330002919 | 1.66 | 90 | Palliative (P) | 2017-05-05 | 2017-05-05 | ECE | 02 | N | 330011257 | BEP |
| 330006152 | 330002919 | 1.63 | null | Palliative (P) | 2015-04-30 | 2015-05-06 | Cyclophosphamide oral | N | N | 330011257 | IVA |
| 330006153 | 330002920 | 1.79 | 56.4 | Neo-adjuvant (N) | 2018-09-10 | 2018-09-12 | EDP + MITOTANE | 2 | N | 330018640 | AML19 TRIAL |
| 330006154 | 330002921 | null | 15.5 | Curative (C) | 2016-05-10 | 2016-05-11 | FCR | null | null | 330019166 | UKALL XII |
| 330006155 | 330007571 | 1.7 | 63.8 | null | 2018-03-23 | 2018-03-28 | CISPLATIN + DOX + ETOPOSIDE + MITOTANE | N | N | 330020704 | FLAG + IDARUBICIN |
| 330006156 | 330007571 | 0 | 69.8 | Adjuvant (A) | 2018-01-31 | 2018-01-31 | IBRUTINIB | 2 | N | 330020704 | TOPOTECAN |
| 330006157 | 330002922 | 1.61 | 7.6 | null | 2018-07-15 | 2018-07-15 | PEMBROLIZUMAB | 02 | N | 330020777 | DOXORUBICIN + IFOSFAMIDE |
| 330006158 | 330002923 | 1.73 | 48.6 | Curative (C) | 2017-02-06 | 2017-02-08 | Bevacizumab | N | Y | 330020858 | AML18 TRIAL |
| 330006159 | 330002924 | 1.58 | 86.2 | Curative (C) | 2018-01-13 | 2018-10-15 | VIDE | 2 | N | 330020928 | EDP + MITOTANE |
| 330006160 | 330002925 | 1.6 | 63 | Curative (C) | 2017-06-07 | 2017-06-21 | AML 19 TRIAL | N | Y | 330021584 | METHOTREXATE |
| 330006161 | 330002926 | 1.61 | 140.6 | Adjuvant (A) | 2018-02-19 | 2018-02-20 | STS Rhabdomyosarcoma RMS 2005 IVA | Y | N | 330023325 | VINBLASTINE |
| 330006162 | 330002927 | 0 | 69 | Curative (C) | 2018-12-29 | 2018-12-29 | STS Rhabdomyosarcoma RMS 2005 IVADo | N | N | 330024821 | IPILIMUMAB + NIVOLUMAB |
| 330006163 | 330002927 | 1.72 | 67 | Palliative (P) | 2017-03-16 | 2017-03-16 | VIDE | N | N | 330024821 | UKALL60+ |
| 330006164 | 330002927 | null | null | Curative (C) | 2018-11-13 | 2018-11-29 | Doxorubicin + Olaratumab | N | N | 330024821 | MIFAMURTIDE |
| 330006165 | 330002928 | null | 54.5 | null | 2018-06-28 | 2018-07-04 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | N | 330019962 | METHOTREXATE INTRATHECAL |
| 330006166 | 330007573 | 1.55 | 85 | Palliative (P) | 2019-05-13 | 2019-05-13 | Bortezomib +/- Dexamethasone | N | N | 330020943 | CARBOPLATIN + RT |
| 330006167 | 330002929 | 0 | 16.75 | Adjuvant (A) | 2015-05-01 | 2015-08-22 | EW Rel rEECur Gemcitabine/Docetaxel | 02 | Y | 330000004 | NOT MATCHED |
| 330006168 | 330012306 | 0.99 | 31.9 | Neo-adjuvant (N) | 2017-05-13 | 2017-05-20 | NB HRNBL-1 COJEC Ind COURSE B | 02 | null | 330000029 | NOT MATCHED |
| 330006169 | 330012306 | 0 | 11 | null | 2013-11-19 | 2013-11-27 | CNS LGG2004 03 vinc + carbo | N | N | 330000029 | NOT MATCHED |
| 330006170 | 330002932 | null | null | Curative (C) | 2018-01-11 | 2018-01-25 | NB HRNBL-1 Isotretinoin | 01 | N | 330000046 | NOT MATCHED |
| 330006171 | 330002933 | null | 47.5 | Curative (C) | 2013-08-11 | 2013-08-14 | NB HRNBL-1 COJEC Ind COURSE A | N | N | 330000047 | NOT MATCHED |
| 330006172 | 330002934 | 1.73 | 16.8 | Curative (C) | 2014-12-31 | 2015-01-03 | NB HRNBL-1 COJEC Ind COURSE C | 01 | null | 330000049 | NOT MATCHED |
| 330006173 | 330002936 | 1.08 | 9.1 | Curative (C) | 2013-09-06 | 2013-09-13 | NB HRNBL-1 COJEC Ind COURSE C | null | Y | 330000050 | NOT MATCHED |
| 330006174 | 330007579 | 0.98 | 17 | Curative (C) | 2015-02-07 | 2015-02-12 | NB HRNBL-1 ch14.18/CHO(trial) +IL-2 | 02 | null | 330000059 | NOT MATCHED |
| 330006175 | 330002941 | 1.88 | 13.3 | Curative (C) | 2015-06-08 | 2015-07-15 | NB HRNBL-1 BUMEL MAT | 1 | Y | 330000065 | NOT MATCHED |
| 330006180 | 330002952 | null | 11.5 | Curative (C) | null | 2013-11-09 | CYCLOPHOSPHAMIDE + ETOPOSIDE + THALIDOMIDE | 02 | null | 330000081 | NOT MATCHED |
| 330006181 | 330002952 | null | 78 | Palliative (P) | 2014-09-13 | 2015-02-23 | AML Downs HA | N | N | 330000081 | NOT MATCHED |
| 330006182 | 330002952 | 1.58 | 75.35 | Neo-adjuvant (N) | null | 2017-12-15 | EW EuroEwing 2012 Arm A VAC | 02 | N | 330000081 | NOT MATCHED |
| 330006183 | 330002955 | 0 | 14.1 | Neo-adjuvant (N) | 2014-12-15 | 2015-02-09 | EW EuroEwing 2012 Arm A VAC | N | N | 330000104 | NOT MATCHED |
| 330006184 | 330002956 | 1.04 | 28.2 | Curative (C) | 2013-10-27 | 2013-12-09 | CNS LGG 2004 03 cons vinc +cyclo | 02 | null | 330000122 | NOT MATCHED |
| 330006185 | 330002958 | null | 11.8 | Neo-adjuvant (N) | 2014-02-24 | 2014-10-17 | EW EuroEwing 2012 Arm A/B BuMEL | 02 | N | 330000123 | NOT MATCHED |
| 330006186 | 330002958 | 0 | 21.8 | null | 2014-03-01 | 2014-03-07 | EW Rel rEECur Gemcitabine/Docetaxel | 02 | N | 330000123 | NOT MATCHED |
| 330006187 | 330007586 | 0 | 24 | Neo-adjuvant (N) | 2017-11-14 | 2017-11-14 | NB HRNBL-1 COJEC Ind COURSE B | Y | N | 330000144 | NOT MATCHED |
| 330006188 | 330002963 | null | 16.5 | Curative (C) | 2014-12-26 | 2015-02-13 | CNS LGG 2004 03 cons vinc +cyclo | N | Y | 330000144 | NOT MATCHED |
| 330006189 | 330002964 | 1.8 | null | Neo-adjuvant (N) | 2013-12-09 | 2013-12-13 | NB HRNBL-1 COJEC Ind COURSE C | N | null | 330000146 | NOT MATCHED |
| 330006190 | 330002965 | null | 4.3 | Disease modification (D) | 2015-09-28 | 2015-09-30 | EW Rel rEECur Topotecan/Cyclophosphamide | null | null | 330000160 | NOT MATCHED |
| 330006191 | 330010136 | 1.62 | 12.5 | Curative (C) | 2018-03-01 | 2018-03-04 | NB HRNBL-1 COJEC Ind COURSE C | Y | Y | 330000163 | NOT MATCHED |
| 330006192 | 330002968 | 1.57 | 58.6 | null | 2017-05-17 | 2017-05-22 | Cisplatin + Radiotherapy | 02 | Y | 330000165 | CISPLATIN + RT |
| 330006193 | 330002969 | null | 84 | Curative (C) | 2016-10-10 | 2017-01-31 | CNS GCT II Germinoma - Ifos Etop | N | Y | 330000172 | NOT MATCHED |
| 330006194 | 330002975 | 1.74 | 59.2 | Curative (C) | 2017-04-12 | 2017-09-23 | null | N | null | 330000180 | NOT MATCHED |
| 330006195 | 330002976 | 0 | 14.8 | Curative (C) | 2011-05-18 | 2014-01-27 | NB HRNBL-1 COJEC Ind COURSE B | N | Y | 330000182 | NOT MATCHED |
| 330006196 | 330002978 | 0 | null | Neo-adjuvant (N) | 2018-01-04 | 2018-02-28 | LCHIV SL-CT 6MP/MTX | null | N | 330000222 | NOT MATCHED |